Recent advances in HTLV-1 research include the development of novel therapeutic agents and immunotherapies aimed at targeting the virus and infected cells. Researchers are also exploring the role of the host immune response in controlling HTLV-1 infection and progression to ATLL. Studies on the molecular mechanisms of HTLV-1-induced carcinogenesis are ongoing, with the aim of identifying new biomarkers and therapeutic targets.
